{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:39:19Z","timestamp":1782823159329,"version":"3.54.5"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":74,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116251","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:51:58Z","timestamp":1769187118000},"page":"116251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Potential induction of protective anti-tumor immune response in cancer patients by oncolytic viruses containing the GGTA1 gene"],"prefix":"10.1016","volume":"236","author":[{"given":"Uri","family":"Galili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116251_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116251_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703 an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116251_bib3","first-page":"S1525","article-title":"Oncolytic viruses as cancer therapeutics: from mechanistic insights to Clin. Trans","volume":"25","author":"Alwithenani","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-024-02104-w","article-title":"Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes","volume":"23","author":"Sun","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2024.12.054","article-title":"Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development","volume":"33","author":"Ayele","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib6","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.ymthe.2025.07.034","article-title":"Oncolytic HSV and cancer drug interactions: current clinical status and future directions","volume":"33","author":"V\u00e1zquez-Arregu\u00edn","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib7","first-page":"13","article-title":"Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment","volume":"10","author":"Chatelain","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2026.116251_bib8","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/1078-0432.CCR-24-3721","article-title":"Measles oncolytic virus as an immunotherapy for recurrent\/refractory pediatric medulloblastoma and atypical teratoid\/rhabdoid tumor: results from PNOC005","volume":"31","author":"Yu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116251_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/CM9.0000000000003585","article-title":"Research progress and development potential of oncolytic vaccinia virus","volume":"138","author":"Zhang","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ejca.2026.116251_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00262-025-04139-4","article-title":"BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy","volume":"74","author":"Park","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116251_bib11","doi-asserted-by":"crossref","first-page":"e01683","DOI":"10.1128\/mBio.01683-18","article-title":"Treatment of human glioblastoma with a live attenuated zika virus vaccine candidate","volume":"9","author":"Chen","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejca.2026.116251_bib12","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/v16111764","article-title":"Differential replication and oncolytic effects of zika virus in aggressive CNS tumor cells: insights from organoid and tumoroid models","volume":"6","author":"Ferreira","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ejca.2026.116251_bib13","doi-asserted-by":"crossref","first-page":"11786","DOI":"10.1128\/JVI.01356-15","article-title":"Retargeting oncolytic vesicular stomatitis virus to human T-cell lymphotropic virus type 1-associated adult T-cell leukemia","volume":"89","author":"Betancourt","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib14","article-title":"Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models","volume":"33","author":"Daniel","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.ejca.2026.116251_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009336","article-title":"Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors","volume":"12","author":"Davar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/v16060886","article-title":"The application of newcastle disease virus (NDV): vaccine vectors and tumor therapy","volume":"16","author":"Yang","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ejca.2026.116251_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/cgt.2012.40","article-title":"Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression","volume":"19","author":"Zhang","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00262-025-04072-6","article-title":"Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models","volume":"74","author":"Pakola","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116251_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as antigen-agnostic cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116251_bib21","first-page":"7","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116251_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.omto.2022.01.009","article-title":"Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer","volume":"24","author":"Rangsitratkul","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ejca.2026.116251_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116251_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/pathogens14020140","article-title":"Oncolytic viruses in ovarian cancer: where do we stand? A narrative review","volume":"14","author":"Borella","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.ejca.2026.116251_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-065X.1997.tb00969.x","article-title":"Antigen localization regulates immune responses in a dose and time dependent fashion: a geographical view of immune reactivity","volume":"156","author":"Zinkernagel","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ejca.2026.116251_bib27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116251_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31083\/j.fbl2702063","article-title":"Oncolytic viruses in melanoma","volume":"27","author":"Robinson","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.ejca.2026.116251_bib30","first-page":"3417","article-title":"Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase","volume":"59","author":"LaTemple","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116251_bib31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0301-472X(02)00956-6","article-title":"Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming","volume":"30","author":"Arina","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ejca.2026.116251_bib32","series-title":"The natural anti-Gal antibody as foe turned friend in medicine","author":"Galili","year":"2018"},{"key":"10.1016\/j.ejca.2026.116251_bib33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1084\/jem.160.5.1519","article-title":"A unique natural human IgG antibody with anti-\u03b1-galactosyl specificity","volume":"160","author":"Galili","year":"1984","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2026.116251_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/cdli.2.2.125-131.1995","article-title":"Human secretions contain IgA, IgG and IgM anti-Gal (anti-\u03b1-galactosyl) antibodies","volume":"2","author":"Hamadeh","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00007890-199708150-00021","article-title":"Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope","volume":"64","author":"McMorrow","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2026.116251_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/glycob\/9.9.865","article-title":"Naturally occurring anti-\u03b1-galactosyl antibodies: relationship to xenoreactive anti-\u03b1-galactosyl antibodies","volume":"9","author":"Parker","year":"1999","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejca.2026.116251_bib37","doi-asserted-by":"crossref","first-page":"M227","DOI":"10.1093\/gerona\/50A.4.M227","article-title":"Variations in activity of the human natural anti-Gal antibody in young and elderly populations","volume":"50A","author":"Wang","year":"1995","journal-title":"J Gerontol (Med Sci)"},{"key":"10.1016\/j.ejca.2026.116251_bib38","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/iai.56.7.1730-1737.1988","article-title":"Interaction between human natural anti-\u03b1-galactosyl immunoglobulin G and bacteria of the human flora","volume":"56","author":"Galili","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.ejca.2026.116251_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1034\/j.1399-3089.2001.00082.x","article-title":"Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural \u03b1 galactosyl IgG antibodies","volume":"8","author":"Ma\u00f1ez","year":"2001","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.ejca.2026.116251_bib40","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood.V82.8.2485.2485","article-title":"One percent of circulating B lymphocytes are capable of producing the natural anti-Gal antibody","volume":"82","author":"Galili","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116251_bib41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1084\/jem.162.2.573","article-title":"Human natural anti-\u03b1-galactosyl IgG. II. The specific recognition of \u03b1(1-3)-linked galactose residues","volume":"162","author":"Galili","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2026.116251_bib42","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1073\/pnas.84.5.1369","article-title":"Evolutionary relationship between the anti-Gal antibody and the Gal\u03b11\u20133Gal epitope in primates","volume":"84","author":"Galili","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2026.116251_bib43","doi-asserted-by":"crossref","first-page":"17755","DOI":"10.1016\/S0021-9258(19)77900-9","article-title":"Man, apes, and Old World monkeys differ from other mammals in the expression of \u03b1-galactosyl epitopes on nucleated cells","volume":"263","author":"Galili","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib44","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0021-9258(19)44247-6","article-title":"Enzymatic synthesis of a blood group B-related pentaglycosylceramide by an alpha-galactosyltransferase from rabbit bone marrow","volume":"248","author":"Basu","year":"1973","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib45","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1016\/S0021-9258(19)69212-4","article-title":"An \u03b1-D-galactosyltransferase in Ehrlich ascites tumor cells: Biosynthesis and characterization of a trisaccharide (\u03b1-D-galacto(1-3)-N-acetyllactosamine)","volume":"256","author":"Blake","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1432-1033.1983.tb07321.x","article-title":"Two alpha-3-D-galactosyltransferases in rabbit stomach mucosa with different acceptor substrate specificities","volume":"32","author":"Betteridge","year":"1983","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.ejca.2026.116251_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-1033.1983.tb07598.x","article-title":"Identification and characterization of an UDP-Gal: N-acetyllactosaminide alpha-1,3-D-galactosyltransferase in calf thymus","volume":"134","author":"Van den Eijnden","year":"1983","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.ejca.2026.116251_bib48","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1073\/pnas.86.21.8227","article-title":"Isolation of a cDNA encoding murine UDP galactose: \u00dfD-galactosyl-1,4-N-acetyl-D-glucosaminide \u03b11,3-galactosyltransferase: Expression cloning by gene transfer","volume":"86","author":"Larsen","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2026.116251_bib49","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1016\/S0021-9258(18)71676-1","article-title":"Bovine \u03b11-3galactosyltransferase: Isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA","volume":"264","author":"Joziasse","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib50","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1073\/pnas.88.16.7401","article-title":"Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys","volume":"88","author":"Galili","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2026.116251_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/imm.13582","article-title":"Paleo-immunology of human anti-carbohydrate antibodies preventing primate extinctions","volume":"168","author":"Galili","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.ejca.2026.116251_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1399-3089.2002.1o058.x","article-title":"Anti-Gal \u03b11\u20133\u2009Gal IgM and IgG antibody levels in sera of humans and Old World non-human primates","volume":"9","author":"Teranishi","year":"2002","journal-title":"Xenotransplantation"},{"issue":"3","key":"10.1016\/j.ejca.2026.116251_bib53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0966-3274(93)90047-C","article-title":"Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man","volume":"1","author":"Cooper","year":"1993","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-065X.1994.tb00877.x","article-title":"Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies","volume":"41","author":"Sandrin","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ejca.2026.116251_bib55","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0167-5699(93)90261-I","article-title":"Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans","volume":"14","author":"Galili","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.ejca.2026.116251_bib56","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.4049\/jimmunol.154.10.5500","article-title":"Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection","volume":"154","author":"Collins","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib57","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.178.7.4676","article-title":"Intratumoral injection of \u03b1-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines","volume":"178","author":"Galili","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib58","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1128\/JVI.00310-06","article-title":"Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Gal\u03b11\u20133Gal\u03b21\u20134GlcNAc-R epitopes","volume":"80","author":"Abdel-Motal","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib59","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1128\/JVI.00647-07","article-title":"Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells","volume":"81","author":"Abdel-Motal","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00027-20","article-title":"Heterosubtypic protection induced by a live attenuated influenza virus vaccine expressing galactose-\u03b1-1,3-galactose epitopes in infected cells","volume":"11","author":"Yan","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ejca.2026.116251_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0167-5699(97)80024-2","article-title":"Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity","volume":"18","author":"Galili","year":"1997","journal-title":"Immunol Today"},{"key":"10.1016\/j.ejca.2026.116251_bib62","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00262-004-0524-x","article-title":"Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer","volume":"53","author":"Galili","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116251_bib63","first-page":"3069","article-title":"Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose","volume":"56","author":"LaTemple","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116251_bib64","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1158\/0008-5472.CAN-05-0627","article-title":"Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes","volume":"65","author":"Rossi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116251_bib65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/glycob\/12.2.135","article-title":"Expression of \u03b1-Gal epitopes (Gal\u03b11\u20133Gal \u03b21\u20134GlcNAc-R) on human cells following transduction with adenovirus vector containing \u03b11,3galactosyltransferase cDNA","volume":"12","author":"Deriy","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejca.2026.116251_bib66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/sj.cgt.7700812","article-title":"In vivo targeting of vaccinating tumor cells to antigen presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene","volume":"12","author":"Deriy","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116251_bib68","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1016\/j.vaccine.2015.08.096","article-title":"Suppression of T cell responses in the tumor microenvironment","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2026.116251_bib69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cancers15030768","article-title":"Combination, modulation and interplay of modern radiotherapy with the tumor microenvironment and targeted therapies in pancreatic cancer: which candidates to boost radiotherapy?","volume":"15","author":"Benkhaled","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116251_bib70","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/biomedicines10081842","article-title":"Therapeutic strategies to enhance tumor antigenicity: making the tumor detectable by the immune system","volume":"10","author":"Meraviglia-Crivelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2026.116251_bib71","doi-asserted-by":"crossref","first-page":"21437","DOI":"10.1074\/jbc.270.37.21437","article-title":"Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse","volume":"270","author":"Thall","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12935-019-1059-8","article-title":"AGI-134: a fully synthetic \u03b1-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models","volume":"19","author":"Shaw","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2026.116251_bib73","first-page":"625","article-title":"Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells","volume":"90","author":"Manches","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2026.116251_bib74","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00262-009-0662-2","article-title":"Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity","volume":"58","author":"Abdel-Motal","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116251_bib75","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12885-015-1973-7","article-title":"Epithelial ovarian cancer stem-like cells expressing \u03b1-gal epitopes increase the immunogenicity of tumor associated antigens","volume":"15","author":"Yao","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184901","article-title":"A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express \u03b1-gal epitopes","volume":"12","author":"Furukawa","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejca.2026.116251_bib77","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2019.01.004","article-title":"Novel fusion cells derived from tumor cells expressing the heterologous \u03b1-galactose epitope and dendritic-cells effectively target cancer","volume":"37","author":"Mo","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2026.116251_bib78","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.3748\/wjg.v17.i48.5260","article-title":"Hepatocellular carcinoma-specific immunotherapy with synthesized \u03b11,3 galactosyl epitope-pulsed dendritic-cells and cytokine-induced killer cells","volume":"17","author":"Qiu","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2026.116251_bib79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcyt.2015.09.012","article-title":"Combination of cytokine-induced killer and dendritic-cells pulsed with antigenic \u03b1-1,3 galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy","volume":"18","author":"Qiu","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejca.2026.116251_bib80","first-page":"3861","article-title":"Cancer immunotherapy by intra-tumoral injection of \u03b1-gal glycolipids","volume":"32","author":"Whalen","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2026.116251_bib81","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116251_bib82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.cgt.7700001","article-title":"Complementary adenoviral vectors for oncolysis","volume":"6","author":"Alemany","year":"1999","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib83","doi-asserted-by":"crossref","first-page":"8934","DOI":"10.1128\/jvi.70.12.8934-8943.1996","article-title":"Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy","volume":"70","author":"Gao","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM196409242711302","article-title":"Observations on repeated administration of viruses to a patient with acute leukemia. A preliminary report","volume":"271","author":"Wheelock","year":"1964","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116251_bib85","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116251_bib86","first-page":"619","article-title":"Attenuated veterinary virus vaccine for the treatment of cancer","volume":"17","author":"Csatary","year":"1993","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.ejca.2026.116251_bib87","first-page":"4","article-title":"An overview on the development of Newcastle disease virus as an anti-cancer therapy","volume":"10","author":"Omar","year":"2003","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.ejca.2026.116251_bib88","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1128\/JVI.02618-05","article-title":"Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines","volume":"80","author":"Krishnamurthy","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib89","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.7150\/ijms.59185","article-title":"Advances in the study of antitumour immunotherapy for newcastle disease virus","volume":"18","author":"Meng","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ejca.2026.116251_bib90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-021-00799-7","article-title":"Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2026.116251_bib91","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1021\/bi00318a038","article-title":"Major oligosaccharides in the glycoprotein of Friend murine leukemia virus: structure elucidation by one- and two-dimensional proton nuclear magnetic resonance and methylation analysis","volume":"2","author":"Geyer","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejca.2026.116251_bib92","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1099\/0022-1317-75-5-1177","article-title":"Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model","volume":"75","author":"Repik","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0264-410X(95)00189-8","article-title":"Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody","volume":"14","author":"Galili","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2026.116251_bib94","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.182.5.1345","article-title":"A novel mechanism of retrovirus inactivation in human serum mediated by anti-\u03b1-galactosyl natural antibody","volume":"182","author":"Rother","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2026.116251_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/379085a0","article-title":"Sensitization of cells and retroviruses to human serum by (\u03b11-3) galactosyltransferase","volume":"379","author":"Takeuchi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116251_bib96","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/JVI.72.6.4650-4656.1998","article-title":"Evaluation of the Gal\u03b11\u20133\u2009Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses","volume":"72","author":"Welsh","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib97","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood.V99.7.2477","article-title":"Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement","volume":"99","author":"Preece","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116251_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2003.09.008","article-title":"The neutralization of pseudorabies virus by anti-\u03b1-galactosyl natural antibody in normal serum","volume":"99","author":"Hayashi","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.ejca.2026.116251_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00567-19","article-title":"Xenoantigen-dependent complement-mediated neutralization of LCMV glycoprotein pseudotyped VSV in human serum","volume":"93","author":"Pipperger","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2026.116251_bib100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-3089.2007.00377.x","article-title":"Natural protection from zoonosis by \u03b1-gal epitopes on virus particles in xenotransmission","volume":"14","author":"Kim","year":"2007","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.ejca.2026.116251_bib101","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.3390\/ijms21186702","article-title":"Host synthesized carbohydrate antigens on viral glycoproteins as \"Achilles' Heel\" of viruses contributing to anti-viral immune protection","volume":"21","author":"Galili","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.116251_bib102","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.tp.0000250598.29377.13","article-title":"Replacement of human anterior cruciate ligaments with pig ligaments: a model for anti-non-gal antibody response in long-term xenotransplantation","volume":"83","author":"Stone","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2026.116251_bib103","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.M709020200","article-title":"Identification of a GH110 subfamily of alpha 1,3-galactosidases: novel enzymes for removal of the alpha 3Gal xenotransplantation antigen","volume":"283","author":"Liu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116251_bib104","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116251_bib105","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2011.02.019","article-title":"The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-\u03b1-1,3-galactose","volume":"127","author":"Commins","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejca.2026.116251_bib106","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11882-015-0512-6","article-title":"Delayed anaphylaxis involving IgE to galactose-\u03b11,3galactose","volume":"15","author":"Platts-Mills","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.ejca.2026.116251_bib107","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/all.16003","article-title":"Tick bites, IgE to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: the alpha-gal syndrome","volume":"79","author":"Wilson","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.ejca.2026.116251_bib108","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/all.12128","article-title":"Identification of galactose-\u03b1-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy","volume":"68","author":"Hamsten","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.ejca.2026.116251_bib109","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/all.12804","article-title":"Haemaphysalis longicornis tick bites are a possible cause of red meat allergy in Japan","volume":"71","author":"Chinuki","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.ejca.2026.116251_bib110","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5694\/j.1326-5377.2009.tb02533.x","article-title":"An association between tick bite reactions and red meat allergy in humans","volume":"190","author":"Van Nunen","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2026.116251_bib111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ab.2007.01.023","volume":"364","author":"Qian","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ejca.2026.116251_bib112","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-016-1846-1","article-title":"Phase I study to evaluate toxicity and feasibility of intratumoral injection of \u03b1-gal glycolipids in patients with advanced melanoma","volume":"65","author":"Albertini","year":"2016","journal-title":"Cancer Immunol Immunother"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:56Z","timestamp":1779380276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":112,"alternative-id":["S0959804926000316"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116251","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential induction of protective anti-tumor immune response in cancer patients by oncolytic viruses containing the GGTA1 gene","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116251"}}